MEG3 has low expression in NSCLC and affects the immunity and autophagy of NSCLC cells via regulating the miR-543/IDO signaling pathway, which is effective for the treatment of NSCLC. This evidence concerns the gene IDO1 and non-small cell lung carcinoma.